Pixantrone was shown to reduce the severity of clinical manifestation in experimental myasthenia gravis. In the present work we further studied its therapeutic effect. Our results demonstrate that a single administration suppressed AChR-specific immune-responses in primed rats. However, clinical symptoms could be improved only by repeated drug administrations (q7dx6 protocol-8.12 mg/kg); this treatment allowed stable serum drug levels for at least 7 days, as assessed by a functional T-cell bioassay. Pixantrone exerted strong in vitro inhibitory effect only on proliferating T-cells without impairing dendritic cell differentiation and B-cell viability. Our data further demonstrate that Pixantrone is a promising immunosuppressant drug that should be investigated in myasthenia gravis. (C) 2013 Elsevier B.V. All rights reserved.

Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis / R. Marolda, C. Ruocco, C. Cordiglieri, C. Toscani, C. Antozzi, R. Mantegazza, F. Baggi. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 258:1-2(2013 May 15), pp. 41-50. [10.1016/j.jneuroim.2013.02.021]

Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis

C. Ruocco
Co-primo
Conceptualization
;
2013

Abstract

Pixantrone was shown to reduce the severity of clinical manifestation in experimental myasthenia gravis. In the present work we further studied its therapeutic effect. Our results demonstrate that a single administration suppressed AChR-specific immune-responses in primed rats. However, clinical symptoms could be improved only by repeated drug administrations (q7dx6 protocol-8.12 mg/kg); this treatment allowed stable serum drug levels for at least 7 days, as assessed by a functional T-cell bioassay. Pixantrone exerted strong in vitro inhibitory effect only on proliferating T-cells without impairing dendritic cell differentiation and B-cell viability. Our data further demonstrate that Pixantrone is a promising immunosuppressant drug that should be investigated in myasthenia gravis. (C) 2013 Elsevier B.V. All rights reserved.
Pixantrone; Acetylcholine receptor (AChR); Experimental autoimmune myasthenia gravis (EAMG); Immunomodulation
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0165572813000593-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.28 MB
Formato Adobe PDF
1.28 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/950882
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 5
social impact